When the long-awaited trial of former Theranos CEO Elizabeth Holmes opens at the end of this month, expect a showdown between defense attorneys and federal prosecutors who have accused her of perpetrating one of the biggest corporate frauds in recent U.S. history.
But perhaps even more striking will be the collision it spotlights between the “move fast and break things” culture of Silicon Valley and the more cautious cadence of health care, where the first rule is to do no harm. Legal experts said the verdict will turn on a narrow set of facts, but its fallout will be more widely felt in the burgeoning biotech and digital health sectors where entrepreneurs are actively raising huge sums of money based on products that often have little evidence behind them.
Create a display name to comment
This name will appear with your comment